Ibrutinib
- Generic Name
- Ibrutinib
- Brand Names
- Imbruvica
- Drug Type
- Small Molecule
- Chemical Formula
- C25H24N6O2
- CAS Number
- 936563-96-1
- Unique Ingredient Identifier
- 1X70OSD4VX
- Background
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell ...
- Indication
Ibrutinib is indicated for the treatment of the following conditions.
Chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)
Waldenström's macroglobulinemia
Chronic graft-versus-host disease (cGVHD)
Mantle cell lymphoma (MCL)
Marginal zone lymphoma (MZL)
- Associated Conditions
- Chronic Graft-Versus-Host Disease, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma (MZL), Refractory Mantle Cell Lymphoma, Relapsed Mantle Cell Lymphoma, Small Lymphocytic Lymphoma, Steroid-dependent chronic graft-versus-host disease, Waldenström's Macroglobulinemia (WM), Steroid refractory Chronic graft versus host disease
- Associated Therapies
- -
PRECISE CURATE.AI Pilot Clinical Trial
- Conditions
- Interventions
- First Posted Date
- 2020-08-21
- Last Posted Date
- 2023-03-29
- Lead Sponsor
- National University Hospital, Singapore
- Target Recruit Count
- 20
- Registration Number
- NCT04522284
- Locations
- 🇸🇬
Ng Teng Fong General Hospital, Singapore, Singapore
🇸🇬National University Hospital, Singapore, Singapore
Ibrutinib With Methotrexate and Temozolomide for Patients With Newly Diagnosed Primary CNS Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2020-08-14
- Last Posted Date
- 2022-04-07
- Lead Sponsor
- Huiqiang Huang
- Target Recruit Count
- 33
- Registration Number
- NCT04514393
- Locations
- 🇨🇳
Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳Department of Hematology Nanfang Hospital, The Southern Medical University, Guandong, Guangdong, China
🇨🇳Guangdong 999 Brain Hospital, Guangzhou, Guangdong, China
Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL
- Conditions
- Interventions
- First Posted Date
- 2020-07-31
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Ascentage Pharma Group Inc.
- Target Recruit Count
- 123
- Registration Number
- NCT04494503
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, Beijing, China
🇨🇳Blood Diseases Hospital Chinese Academy of Medical Sciences, Tianjin, Tianjin, China
🇨🇳The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Study to Assess Effect of Oral Venetoclax Tablet in Combination With Oral Ibrutinib Capsule on Best Overall Response of Complete Response in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2020-07-20
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 6
- Registration Number
- NCT04477486
- Locations
- 🇯🇵
Yamagata University Hospital /ID# 221573, Yamagata-shi, Yamagata, Japan
🇯🇵Aichi Cancer Center Hospital /ID# 221565, Nagoya-shi, Aichi, Japan
🇯🇵Okayama University Hospital /ID# 221623, Okayama-shi, Okayama, Japan
Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma
- First Posted Date
- 2020-06-29
- Last Posted Date
- 2024-01-22
- Lead Sponsor
- Joseph Tuscano
- Target Recruit Count
- 40
- Registration Number
- NCT04450173
- Locations
- 🇺🇸
University of California, Los Angeles, Los Angeles, California, United States
🇺🇸University of California, San Diego, San Diego, California, United States
🇺🇸University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
LOC-R01 Study of Lenalidomide and Ibrutinib in Association With Rituximab-Methotrexate Procarbazine Vincristin (R-MPV)
- Conditions
- Interventions
- First Posted Date
- 2020-06-25
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- Institut Curie
- Target Recruit Count
- 118
- Registration Number
- NCT04446962
- Locations
- 🇫🇷
CHU Besançon, Besançon, France
🇫🇷CHU Amiens, Amiens, France
🇫🇷CHU Angers, Angers, France
Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization
- Conditions
- Interventions
- First Posted Date
- 2020-06-19
- Last Posted Date
- 2023-12-26
- Lead Sponsor
- Jennifer Woyach
- Target Recruit Count
- 10
- Registration Number
- NCT04439006
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Pembrolizumab, Ibrutinib and Rituximab in PCNSL
- Conditions
- Interventions
- First Posted Date
- 2020-06-09
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 37
- Registration Number
- NCT04421560
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Columbia University Medical Center, New York, New York, United States
The Safety and Efficacy of Ibrutinib in Refractory/Relapsed Autoimmune Hemolytic Anemia
- Conditions
- Interventions
- First Posted Date
- 2020-05-21
- Last Posted Date
- 2024-02-12
- Target Recruit Count
- 18
- Registration Number
- NCT04398459
- Locations
- 🇨🇳
Zhoukou Central Hospital, Zhoukou, Henan, China
🇨🇳The Second Affilated Hospital of Shandong First Medical University, Tai'an, Shandong, China
🇨🇳Regenerative Medicine Center, Tianjin, Tianjin, China
Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Pulmonary Injury
- Conditions
- Interventions
- First Posted Date
- 2020-05-05
- Last Posted Date
- 2022-06-01
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 46
- Registration Number
- NCT04375397
- Locations
- 🇺🇸
Stanford University School of Med /ID# 221954, Stanford, California, United States
🇺🇸Midway Immunology and Research /ID# 222004, Fort Pierce, Florida, United States
🇺🇸Triple O Research Institute /ID# 222944, West Palm Beach, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.